AIM ImmunoTech (NYSEAMERICAN:AIM) Shares Up 4.5% – Still a Buy?

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) shares shot up 4.5% on Friday . The stock traded as high as $1.02 and last traded at $0.9589. 1,692,022 shares changed hands during trading, a decline of 83% from the average session volume of 9,676,714 shares. The stock had previously closed at $0.9180.

Wall Street Analyst Weigh In

Separately, Zacks Research lowered AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy”.

AIM ImmunoTech Trading Up 4.5%

The stock has a market capitalization of $3.15 million, a P/E ratio of -0.05 and a beta of 1.26. The company has a 50-day moving average price of $1.03 and a two-hundred day moving average price of $1.64.

Hedge Funds Weigh In On AIM ImmunoTech

A number of institutional investors and hedge funds have recently modified their holdings of the business. DRW Securities LLC increased its stake in shares of AIM ImmunoTech by 60.6% in the 4th quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock valued at $79,000 after acquiring an additional 26,254 shares in the last quarter. Corient Private Wealth LLC bought a new position in AIM ImmunoTech during the second quarter worth $87,000. Finally, Sabby Management LLC bought a new position in AIM ImmunoTech during the third quarter worth $79,000. 12.02% of the stock is currently owned by institutional investors.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.